Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
[HTML][HTML] Immunotherapy for glioma: current management and future application
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial
DA Reardon, AA Brandes, A Omuro… - JAMA …, 2020 - jamanetwork.com
Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
Mechanisms of immunotherapy resistance: lessons from glioblastoma
CM Jackson, J Choi, M Lim - Nature immunology, 2019 - nature.com
Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
Current state of immunotherapy for glioblastoma
M Lim, Y Xia, C Bettegowda, M Weller - Nature reviews Clinical …, 2018 - nature.com
Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
P Chongsathidkiet, C Jackson, S Koyama, F Loebel… - Nature medicine, 2018 - nature.com
T cell dysfunction contributes to tumor immune escape in patients with cancer and is
particularly severe amidst glioblastoma (GBM). Among other defects, T cell lymphopenia is …
particularly severe amidst glioblastoma (GBM). Among other defects, T cell lymphopenia is …
Multidimensional communication in the microenvirons of glioblastoma
Glioblastomas are heterogeneous and invariably lethal tumours. They are characterized by
genetic and epigenetic variations among tumour cells, which makes the development of …
genetic and epigenetic variations among tumour cells, which makes the development of …